TECHNOLOGYJun 6 · 00:00 UTCSCMP WORLDJulie Zhang

Targeting US$610 billion longevity market, biotech firms race to reverse ageing

Biotech firms are targeting a US$610 billion longevity market to reverse aging by reprogramming cellular errors using AI. METiS TechBio CEO Lai Tsai-ta compares aging to software bugs in DNA and suggests AI could repair immune cells like T cells to slow or reverse the process.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Lai Tsai-tapersonMETiS TechBioorganizationlongevity markettopicAItopicT cellstopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 6 · 00:00 UTC
Targeting US$610 billion longevity market, biotech firms race to reverse ageing
HEALTHApr 12 · 05:06 UTC
Method to reverse cellular ageing is about to be tested in humans
SCIENCEMay 27 · 14:18 UTC
In step toward immortality, Israeli scientists say they can ‘rewind’ aging in mouse livers
SCIENCEApr 17 · 02:58 UTC
A “death” protein may be the key to slowing aging at its source
TECHNOLOGYApr 24 · 12:48 UTC
The Rich and Powerful Want to Live Forever. What If They Could?
HEALTHApr 7 · 00:00 UTC
This method to reverse cellular ageing is about to be tested in humans